EDSA Edesa Biotech, Inc.
Edesa Biotech, Inc. (EDSA) is expected to report earnings on November 12, 2026, after the market close. The consensus earnings estimate is a loss of $0.44 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -6.0% since its last earnings release on August 13, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Edesa Biotech, Inc.
Edesa Biotech Inc. is a biopharmaceutical company. It is focused on acquiring, developing and commercializing clinical stage drugs for dermatological and gastrointestinal indications with clear unmet medical needs. The company's product pipeline consists of EB01, EB02 and EB04 which are in clinical stage. Edesa Biotech Inc., formerly known as Stellar Biotechnologies Inc., is based in TORONTO.
Sector
Healthcare
Industry
Biotechnology